Clinical Trial Update: Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Amrubicin was tested as a second-line therapy in advanced/metastatic refractory urothelial carcinoma in a Phase 2 trial; the study was terminated with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Amrubicin (amrubicin)

Snippet

Sponsor: Matthew Galsky | Conditions: Bladder Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-12-24